# GLP-1 Prescribing to Children Aged 8 to 11: Who Gets Them | This GLP Among 3.5 million children aged 8 to 11 with obesity, 0.6% received a GLP-1 prescription, and prescribing skewed toward less socially vulnerable families. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-prescriptions-to-young-children Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Prescribing to Children Aged 8 to 11: Who Gets Them GLP-1 prescriptions to children aged 8 to 11 rose 310-fold in seven years, from a base of 0.03%. The children getting them are the least socially vulnerable. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Prescriptions per 10,000 children with obesity · age · 79.5 (11 years) · 41.5 (8 years) · sex · 75.9 (girls) · 42.8 (boys) · social vulnerability · 76.1 (low) · 49.2 (high) · With an obesity-related condition: 188.9 per 10,000. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 3,520,531 children aged 8 to 11 with obesity and no diabetes were counted from 2019 to 2026. - 0.6% of them received a GLP-1 prescription. - Prevalent prescribing rose from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase, P < .001. - Children with obesity-related conditions were prescribed at 188.9 per 10,000, far above the overall rate. - Children with less social vulnerability were prescribed more: 76.1 against 49.2 per 10,000. Nothing on this site can be bought for a child — every seller in this roster serves adults only, and a prescription for an eight-year-old comes from a pediatrician, not a subscription form. The study is here because the growth figure attached to it is going to be quoted without its base, which is how [most real-world prescribing data](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) gets used. ## The headline and the base Prescribing to this age group rose 310-fold between 2019 and 2026. [\[1\]](https://thisglp.com/research/glp1-prescriptions-to-young-children#ref-1) The starting point was 0.03% of children, so the multiplier is doing what a multiplier does to a very small number. Across the whole cohort of 3.5 million children, 0.6% ever received a prescription. That is uncommon by any reading. Two figures the abstract does not reconcile The published record states that 0.6% of the cohort received a prescription, and separately that prevalent prescribing reached 9.3% in 2026. The second pair is internally consistent, since 0.03% multiplied by 310 is 9.3%. What the indexed abstract does not supply is the denominator that lets a 2026 figure of 9.3% sit beneath a cohort-wide 0.6%. Both are printed here as published. Neither has been adjusted to agree with the other. ## Who is getting them Older children more than younger: 79.5 per 10,000 at age eleven against 41.5 at age eight. Girls more than boys: 75.9 against 42.8. The paper does not explain the second gap and neither will this page. The largest difference is clinical. Children who already had an obesity-related condition were prescribed at 188.9 per 10,000, which the authors read as clinicians reserving these drugs for the highest cardiometabolic risk. That looks like appropriate targeting, and it is the same logic as [an eligibility threshold](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) applied by judgment rather than by rule. ## The finding that runs the wrong way Children with less social vulnerability received more prescriptions: 76.1 per 10,000 against 49.2 among the most vulnerable. Childhood obesity is commoner, not rarer, in the groups getting fewer prescriptions. So access here is tracking resources rather than need, which is the ordinary pattern for an expensive drug and is worth naming when the figure appears inside a paper about prescribing trends. ## What it means for an adult reader Two things, neither of them about children. The first is that a fold-change is not a prevalence, and any number of that shape should send you looking for the base. The second is that who gets a prescription is decided by cost and coverage as much as by clinical need, which is visible in [how few eligible adults ever receive one](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke) and in [where sellers will and will not ship](https://thisglp.com/tools/coverage-by-state). ## Frequently asked How many young children are on these drugs? Few. Across 3,520,531 children aged 8 to 11 with obesity and no diabetes, 0.6% ever received a prescription between 2019 and 2026. What does a 310-fold increase mean? That prevalent prescribing went from 0.03% in 2019 to 9.3% in 2026. The multiplier is large because the starting number was very small. Who is most likely to be prescribed one? Children who already have an obesity-related condition, at 188.9 per 10,000 — well above the rate for any other group measured. Can I buy one for my child from a telehealth seller? No. Every seller covered on this site serves adults only. Prescribing at this age happens through pediatric care. ## Sources 1. \[1\] Orandi BJ, et al. (2026). Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026 Pediatrics. [PMID 42692477](https://pubmed.ncbi.nlm.nih.gov/42692477/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)